HCPLive

Role of Omega-3 in Secondary Prevention of CVD Questioned

Thursday, April 12 (HealthDay News) -- Sang Mi Kwak, M.D., from the Center for Cancer Prevention and Detection in Ilsan, South Korea, and colleagues conducted a meta-analysis of randomized, double-blind, placebo-controlled trials to investigate the efficacy of eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of CVD. The final analyses included 14 trials involving 20,485 patients with a history of CVD.

The researchers found that consuming omega-3 fatty acid supplements was not associated with a significantly reduced risk of overall cardiovascular events (relative risk [RR], 0.99), or with all-cause mortality, sudden cardiac death, myocardial infarction, congestive heart failure, or transient ischemic attack and stroke. The slight reduction in cardiovascular death (RR, 0.91) did not persist when a methodologically flawed study was excluded from the analyses. No significant preventive effect was seen in any of the subgroups analyzed.

"Our meta-analysis showed insufficient evidence of a secondary preventive effect of omega-3 fatty acid supplements against overall cardiovascular events among patients with a history of cardiovascular disease," the authors write.

The majority of the trials included in the study were funded by pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

For patients with a history of cardiovascular disease, evidence is lacking for a secondary preventive effect of omega-3 fatty acid supplements, according to a meta-analysis published online April 9 in the Archives of Internal Medicine.

Copyright © 2012 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
LDL-C was reduced in RA patients who took tocilizumab compared to placebo in a study published in Annals of the Rheumatic Diseases.
When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.
Rheumatoid arthritis patients have increased cardiovascular morbidity and mortality, but tofacitinib can reduce these issues, according to research published in Arthritis & Rheumatology.
$vAR$